Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics, Inc. (VRDN)
:VRDN
RESEARCH TOOLSreports
Holding VRDN?
Track your performance easily
VRDN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.40 - $27.20
Previous CloseN/A
Volume201.32K
Average Volume (3M)1.69M
Market Cap
$1.35B
Enterprise Value$969.97M
Total Cash (Recent Filing)$3.34M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.09
Next Earnings
May 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.31
Shares Outstanding79,212,746
10 Day Avg. Volume1,555,539
30 Day Avg. Volume1,693,028
Standard Deviation0.41
R-Squared0.02
Alpha0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4561.29
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue3.21K
Enterprise Value/Gross Profit3.09K
Enterprise Value/Ebitda-3.88
Forecast
1Y Price Target
$41.00Price Target Upside140.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Viridian Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe THRIVE trial achieved all its primary/secondary endpoints at 15 weeks with a high level of statistical significance.
Financial PositionVRDN is well funded with a balance of cash and equivalents of $753MM at the end of Q3 providing runway into H2:27.
Market PotentialDespite a significant upside move, there is still significant value upside given VRDN's potential in the growing ~$2B TED market.
Bears Say
Efficacy And TolerabilityLinsitinib's efficacy was meaningfully lower than that of Viridian's veligrotug in the pivotal THRIVE study, with a slower onset of efficacy.
Financial RiskA miss could delay the filing, and we see a negative ~$15 impact to our valuation in this scenario.
Market CompetitionLinsitinib is not considered meaningfully competitive with other IGF-1R inhibitors for moderate to severe TED due to its subpar efficacy.
---
Ownership Overview
4.38% Insiders
23.20% Mutual Funds
0.30% Other Institutional Investors
59.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRDN FAQ
What was Viridian Therapeutics, Inc.’s price range in the past 12 months?
Viridian Therapeutics, Inc. lowest stock price was $11.40 and its highest was $27.20 in the past 12 months.
What is Viridian Therapeutics, Inc.’s market cap?
Viridian Therapeutics, Inc.’s market cap is $1.35B.
When is Viridian Therapeutics, Inc.’s upcoming earnings report date?
Viridian Therapeutics, Inc.’s upcoming earnings report date is May 07, 2025 which is in 110 days.
How were Viridian Therapeutics, Inc.’s earnings last quarter?
Viridian Therapeutics, Inc. released its earnings results on Nov 12, 2024. The company reported -$1.15 earnings per share for the quarter, missing the consensus estimate of -$1.057 by -$0.093.
Is Viridian Therapeutics, Inc. overvalued?
According to Wall Street analysts Viridian Therapeutics, Inc.’s price is currently Undervalued.
Does Viridian Therapeutics, Inc. pay dividends?
Viridian Therapeutics, Inc. does not currently pay dividends.
What is Viridian Therapeutics, Inc.’s EPS estimate?
Viridian Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viridian Therapeutics, Inc. have?
Viridian Therapeutics, Inc. has 79,212,746 shares outstanding.
What happened to Viridian Therapeutics, Inc.’s price movement after its last earnings report?
Viridian Therapeutics, Inc. reported an EPS of -$1.15 in its last earnings report, missing expectations of -$1.057. Following the earnings report the stock price went down -12.758%.
Which hedge fund is a major shareholder of Viridian Therapeutics, Inc.?
Among the largest hedge funds holding Viridian Therapeutics, Inc.’s share is Fairmount Funds Management Llc. It holds Viridian Therapeutics, Inc.’s shares valued at 78M.
---
Viridian Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.00 (140.33% Upside)
$41.00 (140.33% Upside)
Blogger Sentiment
Bullish
VRDN Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.84%
12-Months-Change
Fundamentals
Return on Equity
-51.88%
Trailing 12-Months
Asset Growth
134.79%
Trailing 12-Months
Company Description
Viridian Therapeutics, Inc.
Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
---
VRDN Company Deck
---
VRDN Earnings Call
Q1 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects significant progress and positive developments in the company's pipeline, particularly with the completion of enrollment in the THRIVE trial, a strong financial position, and positive regulatory interactions. However, there are challenges, such as the extended timeline for BLA submission and concerns about hearing impairment assessments in clinical trials.Read More>---
VRDN Stock 12 Month Forecast
Average Price Target
$41.00
▲(140.33% Upside)
Technical Analysis
Annovis Bio
―
Kiniksa Pharmaceuticals
―
Seres Therapeutics
―
Ardelyx
―
Rigel
―
Fate Therapeutics
―
Best Analysts Covering VRDN
1 Year
1 Year Success Rate
19/38 ratings generated profit
1 Year Average Return
+1.80%
reiterated a buy rating 11 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +1.80% per trade.
---